Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer
Identifieur interne : 00B119 ( Main/Exploration ); précédent : 00B118; suivant : 00B120Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer
Auteurs : Masahiro Fukuoka [Japon, France, Belgique, Australie, Afrique du Sud, Pays-Bas, États-Unis, Royaume-Uni, Espagne] ; Seiji Yano ; Giuseppe Giaccone ; Tomohide Tamura ; Kazuhiko Nakagawa ; Jean-Yves Douillard ; Yutaka Nishiwaki ; Johan Vansteenkiste ; Shinzoh Kudoh ; Danny Rischin ; Richard Eek ; Takeshi Horai ; Kazumasa Noda ; Ichiro Takata ; Egbert Smit ; Steven Averbuch ; Angela Macleod ; Andrea Feyereislova ; Rui-Ping Dong ; José BaselgaSource :
- Journal of clinical oncology [ 0732-183X ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Carcinome non petite cellule, Bronchopulmonaire, Stade avancé, Inhibiteur enzyme, Protein-tyrosine kinase, Anticancéreux, Essai clinique phase II, Chimiothérapie, Traitement, Voie orale, Prétraitement, Platine Complexe, Randomisation, Efficacité traitement, Toxicité, Complication, Etude multicentrique, Homme, Géfitinib.
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Advanced stage, Antineoplastic agent, Bronchopulmonary, Chemotherapy, Complication, Enzyme inhibitor, Human, Multicenter study, Non small cell carcinoma, Oral administration, Phase II trial, Platinum Complexes, Pretreatment, Protein-tyrosine kinase, Randomization, Toxicity, Treatment, Treatment efficiency.
Abstract
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilming-ton, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC). Patients and Methods: This was a randomized, double-blind, parallel-group, multicenter phase II trial. Two hundred ten patients with advanced NSCLC who were previously treated with one or two chemotherapy regimens (at least one containing platinum) were randomized to receive either 250-mg or 500-mg oral doses of gefitinib once daily. Results: Efficacy was similar for the 250- and 500-mg/d groups. Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% Cl, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% Cl, 28.5 to 53.0) and 37.0% (95% Cl, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively. Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response. Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Drug-related toxicities were more frequent in the higher-dose group. Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively. Conclusion: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients. At 250 mg/d, gefitinib had a favorable AE profile. Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
Affiliations:
- Afrique du Sud, Australie, Belgique, Espagne, France, Japon, Pays-Bas, Royaume-Uni, États-Unis
- Catalogne, Hollande-Septentrionale, Région de Kantō, Victoria (État)
- Amsterdam, Barcelone, Melbourne, Tokyo
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 005179
- to stream PascalFrancis, to step Curation: 000F47
- to stream PascalFrancis, to step Checkpoint: 004E93
- to stream Main, to step Merge: 00BE78
- to stream Main, to step Curation: 00B119
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer</title><author><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Kinki University School of Medicine, Osaka City University School of Medicine, and AstraZeneca</s1><s2>Osaka</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Osaka</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Tokushima University School of Medicine</s1><s2>Tokushima</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Tokushima University School of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>National Cancer Center, Central Hospital, and Japanese Foundation for Cancer Research</s1><s2>Tokyo</s2><s3>JPN</s3></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>National Cancer Center, East Hospital</s1><s2>Chiba</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Kanagawa Cancer Center</s1><s2>Yokohama</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Kanagawa Cancer Center</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>National Shikoku Cancer Center</s1><s2>Matsuyama</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>National Shikoku Cancer Center</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>C.R.L.C.C. Rene Gauducheau</s1><s2>Saint-Herblain</s2><s3>FRA</s3></inist:fA14><country>France</country><wicri:noRegion>Saint-Herblain</wicri:noRegion><wicri:noRegion>C.R.L.C.C. Rene Gauducheau</wicri:noRegion><wicri:noRegion>C.R.L.C.C. Rene Gauducheau</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University Hospital Gasthuisberg</s1><s2>Leuven</s2><s3>BEL</s3></inist:fA14><country>Belgique</country><wicri:noRegion>University Hospital Gasthuisberg</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Centre for Developmental Cancer Therapeutics</s1><s2>Melbourne</s2><s3>AUS</s3></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Mary Potter Oncology Centre</s1><s2>Pretoria</s2><s3>ZAF</s3></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mary Potter Oncology Centre</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Academic Hospital Free University</s1><s2>Amsterdam</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>AstraZeneca</s1><s2>Wilmington, DE</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>AstraZeneca</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>AstraZeneca, Alderley Park</s1><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>AstraZeneca, Alderley Park</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="14"><s1>Vall d'Hebron University Hospital</s1><s2>Barcelona</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Yano, Seiji" sort="Yano, Seiji" uniqKey="Yano S" first="Seiji" last="Yano">Seiji Yano</name></author><author><name sortKey="Giaccone, Giuseppe" sort="Giaccone, Giuseppe" uniqKey="Giaccone G" first="Giuseppe" last="Giaccone">Giuseppe Giaccone</name></author><author><name sortKey="Tamura, Tomohide" sort="Tamura, Tomohide" uniqKey="Tamura T" first="Tomohide" last="Tamura">Tomohide Tamura</name></author><author><name sortKey="Nakagawa, Kazuhiko" sort="Nakagawa, Kazuhiko" uniqKey="Nakagawa K" first="Kazuhiko" last="Nakagawa">Kazuhiko Nakagawa</name></author><author><name sortKey="Douillard, Jean Yves" sort="Douillard, Jean Yves" uniqKey="Douillard J" first="Jean-Yves" last="Douillard">Jean-Yves Douillard</name></author><author><name sortKey="Nishiwaki, Yutaka" sort="Nishiwaki, Yutaka" uniqKey="Nishiwaki Y" first="Yutaka" last="Nishiwaki">Yutaka Nishiwaki</name></author><author><name sortKey="Vansteenkiste, Johan" sort="Vansteenkiste, Johan" uniqKey="Vansteenkiste J" first="Johan" last="Vansteenkiste">Johan Vansteenkiste</name></author><author><name sortKey="Kudoh, Shinzoh" sort="Kudoh, Shinzoh" uniqKey="Kudoh S" first="Shinzoh" last="Kudoh">Shinzoh Kudoh</name></author><author><name sortKey="Rischin, Danny" sort="Rischin, Danny" uniqKey="Rischin D" first="Danny" last="Rischin">Danny Rischin</name></author><author><name sortKey="Eek, Richard" sort="Eek, Richard" uniqKey="Eek R" first="Richard" last="Eek">Richard Eek</name></author><author><name sortKey="Horai, Takeshi" sort="Horai, Takeshi" uniqKey="Horai T" first="Takeshi" last="Horai">Takeshi Horai</name></author><author><name sortKey="Noda, Kazumasa" sort="Noda, Kazumasa" uniqKey="Noda K" first="Kazumasa" last="Noda">Kazumasa Noda</name></author><author><name sortKey="Takata, Ichiro" sort="Takata, Ichiro" uniqKey="Takata I" first="Ichiro" last="Takata">Ichiro Takata</name></author><author><name sortKey="Smit, Egbert" sort="Smit, Egbert" uniqKey="Smit E" first="Egbert" last="Smit">Egbert Smit</name></author><author><name sortKey="Averbuch, Steven" sort="Averbuch, Steven" uniqKey="Averbuch S" first="Steven" last="Averbuch">Steven Averbuch</name></author><author><name sortKey="Macleod, Angela" sort="Macleod, Angela" uniqKey="Macleod A" first="Angela" last="Macleod">Angela Macleod</name></author><author><name sortKey="Feyereislova, Andrea" sort="Feyereislova, Andrea" uniqKey="Feyereislova A" first="Andrea" last="Feyereislova">Andrea Feyereislova</name></author><author><name sortKey="Dong, Rui Ping" sort="Dong, Rui Ping" uniqKey="Dong R" first="Rui-Ping" last="Dong">Rui-Ping Dong</name></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="José" last="Baselga">José Baselga</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">03-0461261</idno><date when="2003">2003</date><idno type="stanalyst">PASCAL 03-0461261 INIST</idno><idno type="RBID">Pascal:03-0461261</idno><idno type="wicri:Area/PascalFrancis/Corpus">005179</idno><idno type="wicri:Area/PascalFrancis/Curation">000F47</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">004E93</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004E93</idno><idno type="wicri:doubleKey">0732-183X:2003:Fukuoka M:multi:institutional:randomized</idno><idno type="wicri:Area/Main/Merge">00BE78</idno><idno type="wicri:Area/Main/Curation">00B119</idno><idno type="wicri:Area/Main/Exploration">00B119</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer</title><author><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Kinki University School of Medicine, Osaka City University School of Medicine, and AstraZeneca</s1><s2>Osaka</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Osaka</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Tokushima University School of Medicine</s1><s2>Tokushima</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Tokushima University School of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>National Cancer Center, Central Hospital, and Japanese Foundation for Cancer Research</s1><s2>Tokyo</s2><s3>JPN</s3></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>National Cancer Center, East Hospital</s1><s2>Chiba</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Kanagawa Cancer Center</s1><s2>Yokohama</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Kanagawa Cancer Center</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>National Shikoku Cancer Center</s1><s2>Matsuyama</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>National Shikoku Cancer Center</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>C.R.L.C.C. Rene Gauducheau</s1><s2>Saint-Herblain</s2><s3>FRA</s3></inist:fA14><country>France</country><wicri:noRegion>Saint-Herblain</wicri:noRegion><wicri:noRegion>C.R.L.C.C. Rene Gauducheau</wicri:noRegion><wicri:noRegion>C.R.L.C.C. Rene Gauducheau</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>University Hospital Gasthuisberg</s1><s2>Leuven</s2><s3>BEL</s3></inist:fA14><country>Belgique</country><wicri:noRegion>University Hospital Gasthuisberg</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Centre for Developmental Cancer Therapeutics</s1><s2>Melbourne</s2><s3>AUS</s3></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Mary Potter Oncology Centre</s1><s2>Pretoria</s2><s3>ZAF</s3></inist:fA14><country>Afrique du Sud</country><wicri:noRegion>Mary Potter Oncology Centre</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Academic Hospital Free University</s1><s2>Amsterdam</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>AstraZeneca</s1><s2>Wilmington, DE</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>AstraZeneca</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>AstraZeneca, Alderley Park</s1><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>AstraZeneca, Alderley Park</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="14"><s1>Vall d'Hebron University Hospital</s1><s2>Barcelona</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Yano, Seiji" sort="Yano, Seiji" uniqKey="Yano S" first="Seiji" last="Yano">Seiji Yano</name></author><author><name sortKey="Giaccone, Giuseppe" sort="Giaccone, Giuseppe" uniqKey="Giaccone G" first="Giuseppe" last="Giaccone">Giuseppe Giaccone</name></author><author><name sortKey="Tamura, Tomohide" sort="Tamura, Tomohide" uniqKey="Tamura T" first="Tomohide" last="Tamura">Tomohide Tamura</name></author><author><name sortKey="Nakagawa, Kazuhiko" sort="Nakagawa, Kazuhiko" uniqKey="Nakagawa K" first="Kazuhiko" last="Nakagawa">Kazuhiko Nakagawa</name></author><author><name sortKey="Douillard, Jean Yves" sort="Douillard, Jean Yves" uniqKey="Douillard J" first="Jean-Yves" last="Douillard">Jean-Yves Douillard</name></author><author><name sortKey="Nishiwaki, Yutaka" sort="Nishiwaki, Yutaka" uniqKey="Nishiwaki Y" first="Yutaka" last="Nishiwaki">Yutaka Nishiwaki</name></author><author><name sortKey="Vansteenkiste, Johan" sort="Vansteenkiste, Johan" uniqKey="Vansteenkiste J" first="Johan" last="Vansteenkiste">Johan Vansteenkiste</name></author><author><name sortKey="Kudoh, Shinzoh" sort="Kudoh, Shinzoh" uniqKey="Kudoh S" first="Shinzoh" last="Kudoh">Shinzoh Kudoh</name></author><author><name sortKey="Rischin, Danny" sort="Rischin, Danny" uniqKey="Rischin D" first="Danny" last="Rischin">Danny Rischin</name></author><author><name sortKey="Eek, Richard" sort="Eek, Richard" uniqKey="Eek R" first="Richard" last="Eek">Richard Eek</name></author><author><name sortKey="Horai, Takeshi" sort="Horai, Takeshi" uniqKey="Horai T" first="Takeshi" last="Horai">Takeshi Horai</name></author><author><name sortKey="Noda, Kazumasa" sort="Noda, Kazumasa" uniqKey="Noda K" first="Kazumasa" last="Noda">Kazumasa Noda</name></author><author><name sortKey="Takata, Ichiro" sort="Takata, Ichiro" uniqKey="Takata I" first="Ichiro" last="Takata">Ichiro Takata</name></author><author><name sortKey="Smit, Egbert" sort="Smit, Egbert" uniqKey="Smit E" first="Egbert" last="Smit">Egbert Smit</name></author><author><name sortKey="Averbuch, Steven" sort="Averbuch, Steven" uniqKey="Averbuch S" first="Steven" last="Averbuch">Steven Averbuch</name></author><author><name sortKey="Macleod, Angela" sort="Macleod, Angela" uniqKey="Macleod A" first="Angela" last="Macleod">Angela Macleod</name></author><author><name sortKey="Feyereislova, Andrea" sort="Feyereislova, Andrea" uniqKey="Feyereislova A" first="Andrea" last="Feyereislova">Andrea Feyereislova</name></author><author><name sortKey="Dong, Rui Ping" sort="Dong, Rui Ping" uniqKey="Dong R" first="Rui-Ping" last="Dong">Rui-Ping Dong</name></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="José" last="Baselga">José Baselga</name></author></analytic><series><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno><imprint><date when="2003">2003</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Antineoplastic agent</term><term>Bronchopulmonary</term><term>Chemotherapy</term><term>Complication</term><term>Enzyme inhibitor</term><term>Human</term><term>Multicenter study</term><term>Non small cell carcinoma</term><term>Oral administration</term><term>Phase II trial</term><term>Platinum Complexes</term><term>Pretreatment</term><term>Protein-tyrosine kinase</term><term>Randomization</term><term>Toxicity</term><term>Treatment</term><term>Treatment efficiency</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Carcinome non petite cellule</term><term>Bronchopulmonaire</term><term>Stade avancé</term><term>Inhibiteur enzyme</term><term>Protein-tyrosine kinase</term><term>Anticancéreux</term><term>Essai clinique phase II</term><term>Chimiothérapie</term><term>Traitement</term><term>Voie orale</term><term>Prétraitement</term><term>Platine Complexe</term><term>Randomisation</term><term>Efficacité traitement</term><term>Toxicité</term><term>Complication</term><term>Etude multicentrique</term><term>Homme</term><term>Géfitinib</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilming-ton, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC). Patients and Methods: This was a randomized, double-blind, parallel-group, multicenter phase II trial. Two hundred ten patients with advanced NSCLC who were previously treated with one or two chemotherapy regimens (at least one containing platinum) were randomized to receive either 250-mg or 500-mg oral doses of gefitinib once daily. Results: Efficacy was similar for the 250- and 500-mg/d groups. Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% Cl, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% Cl, 28.5 to 53.0) and 37.0% (95% Cl, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively. Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response. Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Drug-related toxicities were more frequent in the higher-dose group. Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively. Conclusion: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients. At 250 mg/d, gefitinib had a favorable AE profile. Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>Australie</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Japon</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Catalogne</li><li>Hollande-Septentrionale</li><li>Région de Kantō</li><li>Victoria (État)</li></region><settlement><li>Amsterdam</li><li>Barcelone</li><li>Melbourne</li><li>Tokyo</li></settlement></list><tree><noCountry><name sortKey="Averbuch, Steven" sort="Averbuch, Steven" uniqKey="Averbuch S" first="Steven" last="Averbuch">Steven Averbuch</name><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="José" last="Baselga">José Baselga</name><name sortKey="Dong, Rui Ping" sort="Dong, Rui Ping" uniqKey="Dong R" first="Rui-Ping" last="Dong">Rui-Ping Dong</name><name sortKey="Douillard, Jean Yves" sort="Douillard, Jean Yves" uniqKey="Douillard J" first="Jean-Yves" last="Douillard">Jean-Yves Douillard</name><name sortKey="Eek, Richard" sort="Eek, Richard" uniqKey="Eek R" first="Richard" last="Eek">Richard Eek</name><name sortKey="Feyereislova, Andrea" sort="Feyereislova, Andrea" uniqKey="Feyereislova A" first="Andrea" last="Feyereislova">Andrea Feyereislova</name><name sortKey="Giaccone, Giuseppe" sort="Giaccone, Giuseppe" uniqKey="Giaccone G" first="Giuseppe" last="Giaccone">Giuseppe Giaccone</name><name sortKey="Horai, Takeshi" sort="Horai, Takeshi" uniqKey="Horai T" first="Takeshi" last="Horai">Takeshi Horai</name><name sortKey="Kudoh, Shinzoh" sort="Kudoh, Shinzoh" uniqKey="Kudoh S" first="Shinzoh" last="Kudoh">Shinzoh Kudoh</name><name sortKey="Macleod, Angela" sort="Macleod, Angela" uniqKey="Macleod A" first="Angela" last="Macleod">Angela Macleod</name><name sortKey="Nakagawa, Kazuhiko" sort="Nakagawa, Kazuhiko" uniqKey="Nakagawa K" first="Kazuhiko" last="Nakagawa">Kazuhiko Nakagawa</name><name sortKey="Nishiwaki, Yutaka" sort="Nishiwaki, Yutaka" uniqKey="Nishiwaki Y" first="Yutaka" last="Nishiwaki">Yutaka Nishiwaki</name><name sortKey="Noda, Kazumasa" sort="Noda, Kazumasa" uniqKey="Noda K" first="Kazumasa" last="Noda">Kazumasa Noda</name><name sortKey="Rischin, Danny" sort="Rischin, Danny" uniqKey="Rischin D" first="Danny" last="Rischin">Danny Rischin</name><name sortKey="Smit, Egbert" sort="Smit, Egbert" uniqKey="Smit E" first="Egbert" last="Smit">Egbert Smit</name><name sortKey="Takata, Ichiro" sort="Takata, Ichiro" uniqKey="Takata I" first="Ichiro" last="Takata">Ichiro Takata</name><name sortKey="Tamura, Tomohide" sort="Tamura, Tomohide" uniqKey="Tamura T" first="Tomohide" last="Tamura">Tomohide Tamura</name><name sortKey="Vansteenkiste, Johan" sort="Vansteenkiste, Johan" uniqKey="Vansteenkiste J" first="Johan" last="Vansteenkiste">Johan Vansteenkiste</name><name sortKey="Yano, Seiji" sort="Yano, Seiji" uniqKey="Yano S" first="Seiji" last="Yano">Seiji Yano</name></noCountry><country name="Japon"><noRegion><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></noRegion><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></country><country name="France"><noRegion><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></noRegion></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></region></country><country name="Afrique du Sud"><noRegion><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></region></country><country name="États-Unis"><noRegion><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></noRegion></country><country name="Espagne"><region name="Catalogne"><name sortKey="Fukuoka, Masahiro" sort="Fukuoka, Masahiro" uniqKey="Fukuoka M" first="Masahiro" last="Fukuoka">Masahiro Fukuoka</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00B119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00B119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:03-0461261
|texte= Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer
}}
| This area was generated with Dilib version V0.6.33. |  |